Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Susceptibility testing breakpoints for Mycobacterium tuberculosis categorize isolates with resistance mutations in gyrA as susceptible to fluoroquinolones: implications for MDR-TB treatment and the definition of XDR-TB.
Niward K, Ängeby K, Chryssanthou E, Paues J, Bruchfeld J, Jureen P, Giske CG, Kahlmeter G, Schön T. Niward K, et al. J Antimicrob Chemother. 2016 Feb;71(2):333-8. doi: 10.1093/jac/dkv353. Epub 2015 Nov 3. J Antimicrob Chemother. 2016. PMID: 26538509
Plasma Levels of Rifampin Correlate with the Tuberculosis Drug Activity Assay.
Niward K, Ek Blom L, Davies Forsman L, Bruchfeld J, Eliasson E, Schön T, Chryssanthou E, Paues J. Niward K, et al. Antimicrob Agents Chemother. 2018 Apr 26;62(5):e00218-18. doi: 10.1128/AAC.00218-18. Print 2018 May. Antimicrob Agents Chemother. 2018. PMID: 29483112 Free PMC article.
Distribution of plasma concentrations of first-line anti-TB drugs and individual MICs: a prospective cohort study in a low endemic setting.
Niward K, Davies Forsman L, Bruchfeld J, Chryssanthou E, Carlström O, Alomari T, Carlsson B, Pohanka A, Mansjö M, Jonsson Nordvall M, Johansson AG, Eliasson E, Werngren J, Paues J, Simonsson USH, Schön T. Niward K, et al. J Antimicrob Chemother. 2018 Oct 1;73(10):2838-2845. doi: 10.1093/jac/dky268. J Antimicrob Chemother. 2018. PMID: 30124844
Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study.
Davies Forsman L, Niward K, Hu Y, Zheng R, Zheng X, Ke R, Cai W, Hong C, Li Y, Gao Y, Werngren J, Paues J, Kuhlin J, Simonsson USH, Eliasson E, Alffenaar JW, Mansjö M, Hoffner S, Xu B, Schön T, Bruchfeld J. Davies Forsman L, et al. Among authors: niward k. BMJ Open. 2018 Oct 4;8(9):e023899. doi: 10.1136/bmjopen-2018-023899. BMJ Open. 2018. PMID: 30287613 Free PMC article.
Sedimentation rate and suPAR in relation to disease activity and mortality in patients with tuberculosis.
Schulman H, Niward K, Abate E, Idh J, Axenram P, Bornefall A, Forsgren S, Jakobsson J, Öhrling C, Kron M, Brudin L, Diro E, Getachew Kebede A, Paues J, Bruchfeld J, Wejse C, Stendahl O, Schön T. Schulman H, et al. Among authors: niward k. Int J Tuberc Lung Dis. 2019 Nov 1;23(11):1155-1161. doi: 10.5588/ijtld.18.0634. Int J Tuberc Lung Dis. 2019. PMID: 31718751
Development and validation of a simple LC-MS/MS method for simultaneous determination of moxifloxacin, levofloxacin, prothionamide, pyrazinamide and ethambutol in human plasma.
Zheng X, Jongedijk EM, Hu Y, Kuhlin J, Zheng R, Niward K, Paues J, Xu B, Davies Forsman L, Schön T, Bruchfeld J, Alffenaar JC. Zheng X, et al. Among authors: niward k. J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Nov 20;1158:122397. doi: 10.1016/j.jchromb.2020.122397. Epub 2020 Oct 8. J Chromatogr B Analyt Technol Biomed Life Sci. 2020. PMID: 33091676
Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China.
Davies Forsman L, Niward K, Kuhlin J, Zheng X, Zheng R, Ke R, Hong C, Werngren J, Paues J, Simonsson USH, Eliasson E, Hoffner S, Xu B, Alffenaar JW, Schön T, Hu Y, Bruchfeld J. Davies Forsman L, et al. Among authors: niward k. Eur Respir J. 2021 Mar 11;57(3):2003463. doi: 10.1183/13993003.03463-2020. Print 2021 Mar. Eur Respir J. 2021. PMID: 33154028 Free article. No abstract available.
Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP).
Ekqvist D, Bornefall A, Augustinsson D, Sönnerbrandt M, Nordvall MJ, Fredrikson M, Carlsson B, Sandstedt M, Simonsson USH, Alffenaar JC, Paues J, Niward K. Ekqvist D, et al. Among authors: niward k. BMJ Open. 2022 Mar 10;12(3):e054788. doi: 10.1136/bmjopen-2021-054788. BMJ Open. 2022. PMID: 35273049 Free PMC article.
23 results